PAX2 and hepatocellular carcinoma: In another study, the expression of exosomal miR-744 in the sera of HCC patients was lower than that in the sera of healthy individuals, demonstrating that low levels of miR-744 promoted the resistance of HCC cells to sorafenib and that PAX2 was a direct target of miR-744 [98].